Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Alliance Grants

University of Alberta

$30,000.00

Data-driven optimal control for continuous monoclonal antibodies manufacturing

FY 2023-24

Summary
Drugs based on monoclonal antibodies (mAbs) play an indispensable role in bio-pharmaceutical industry in aspects of therapeutic and market potentials. Increasing the production capacity of mAb manufacturing processes is immediately necessary due to the explosive growth in mAb market. Replacing the current batch processes by continuous manufacturing processes is recognized as the solution to address the explosive market needs. In a previous Alliance project, we have developed an optimal control approach to handle the frequent switching operations in continuous mAb manufacturing by integrating control theory and artificial intelligence. In this proposed project, we continue our collaboration with Quartic.ai to significantly simplify the design of the optimal controller designed in the previous project. In the proposed project, we will take advantage of the available process data to find the control invariant set of the process according to a performance measure related to the quality of the product. And then integrate the control invariant set with the previous developed optimal control algorithm to ensure closed-loop stability. Constructing control invariant sets using process data for systems with manipulated inputs has received little attention and this project will fill the knowledge gap. Canada is an active and competitive contributor to the development of high capacity mAb manufacturing processes. This project will (a) further enhance the competitiveness of Canada in biopharmaceutical industry, (b) train highly qualified personnel (HQP) that have interdisciplinary backgrounds in biopharmaceutical and control engineering, and (c) create more job opportunities in Quartic.ai in the near future.
Program
Alliance Grants
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
581121-2022
Name nom
Liu, Jinfeng J
Department département
Chemical and Materials Engineering
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2022
Award amount
30000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Not available
Research subject en
Non disponible
Research subject fr
Non disponible
Application title
Data-driven optimal control for continuous monoclonal antibodies manufacturing
Keyword
Artificial intelligence; Biopharmaceutical processes; Control invariant set; Data-driven; Graph theory; Monoclonal antibodies manufacturing; Optimal control; Stability
Application summary
Drugs based on monoclonal antibodies (mAbs) play an indispensable role in bio-pharmaceutical industry in aspects of therapeutic and market potentials. Increasing the production capacity of mAb manufacturing processes is immediately necessary due to the explosive growth in mAb market. Replacing the current batch processes by continuous manufacturing processes is recognized as the solution to address the explosive market needs. In a previous Alliance project, we have developed an optimal control approach to handle the frequent switching operations in continuous mAb manufacturing by integrating control theory and artificial intelligence. In this proposed project, we continue our collaboration with Quartic.ai to significantly simplify the design of the optimal controller designed in the previous project. In the proposed project, we will take advantage of the available process data to find the control invariant set of the process according to a performance measure related to the quality of the product. And then integrate the control invariant set with the previous developed optimal control algorithm to ensure closed-loop stability. Constructing control invariant sets using process data for systems with manipulated inputs has received little attention and this project will fill the knowledge gap. Canada is an active and competitive contributor to the development of high capacity mAb manufacturing processes. This project will (a) further enhance the competitiveness of Canada in biopharmaceutical industry, (b) train highly qualified personnel (HQP) that have interdisciplinary backgrounds in biopharmaceutical and control engineering, and (c) create more job opportunities in Quartic.ai in the near future.